Assessment of bee venom therapy in animal model of statin-induced myopathy

• Main Authors: Ann Abdel Kader, Radwa Azmy, Eman A. Maher, Basma Bahgat El Sayed, Alshaimaa Sobhi Khalil, Mohammad Ghalwash, Manal Mahmoud
• Format: Article
• Language: English
• Published: SpringerOpen 2019-11-01
• Series: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
• Subjects: Statin-induced myopathy; Bee venom; QEMG; Muscle contractility
• Online Access: http://link.springer.com/article/10.1186/s41983-019-0120-9

Abstract Background Statin-induced myopathy is the most common adverse effect of statins. Bee venom provides a potential mean of controlling immune responses and inflammatory reactions; the proposed mechanisms for statin-induced myopathy. Objective The present study aimed at clarification of the role of the bee venom in prevention of statin-induced myopathy. Materials and methods It was carried out on 30 Sprague-Dawley female rats. Rats were randomly classified into 3 groups: control group, statin group which received statins for 2 weeks, and venom group that was exposed to alternate day actual bee sting concurrent to statins administration for 2 weeks. Quantitative electromyography (QEMG) was performed as well as serum creatine kinase (CK) and cholesterol levels, in addition to in vitro muscle contractility tests. Results QEMG and contractility tests showed significant changes in the statin group compared to both control and venom groups. Serum cholesterol level decreased with increase in CK levels in the statin and venom groups compared to controls; however, the CK level was significantly lower in the venom group as compared to the statin group. Conclusion Bee venom therapy offers a simple and available means of prophylaxis against the myopathic effects induced by statins in animal model. However, it partly restricts the therapeutic effect of statins.